AI in Drug Development 2026: The Shift to Execution
About this event
On ths webinar Sara Mallatt, AlphaSense’s Director of Healthcare Research and Dr. Paul Agapow, former Director of Data Science at GSK, explored how AI is transforming medicine. They discussed whether AI is on track to make drug development faster, cheaper, and more successful.
AI in Drug Development 2026: The Shift to Execution is a webinar from AlphaSense focused on AI and Data. See AlphaSense's website for confirmed availability and schedule details. UPCOMING provides an independent event listing and directs attendees to AlphaSense's website to complete registration or viewing.
What you'll learn
- The "Autonomous Lab" Shift: How robotics and AI are closing the loop in R&D.
- Regulatory Evolution: Navigating the new global rules for AI-assisted approvals.
- The Major Strategic Moves: How dealmaking is redefining the competition between pharma giants and the new wave of "TechBios.”
Topics covered
Frequently asked questions
Who is hosting AI in Drug Development 2026: The Shift to Execution?
AI in Drug Development 2026: The Shift to Execution is hosted by AlphaSense.
When is AI in Drug Development 2026: The Shift to Execution?
See the official event page for AI in Drug Development 2026: The Shift to Execution's confirmed availability and schedule details.
Where does registration take place?
Registration or viewing is completed on AlphaSense's website.
What format is this event?
This is an online webinar.
Which topics does this event cover?
The event covers AI and Data.
